中疾控启动集中采购，二价HPV疫苗免费接种越来越近了！

Core Insights - The Chinese government has included the HPV vaccine in the national immunization program, with a centralized procurement project for the bivalent HPV vaccine set for 2025, with a budget of approximately 425 million yuan and a total quantity of 15.4465 million doses, indicating a maximum price of 27.5 yuan per dose [1][2][3] Group 1: Procurement Details - The procurement unit is the Chinese Center for Disease Control and Prevention [2] - The project budget is 424.78 million yuan, with a total of 15.4465 million doses required [2] - The specifications for the vaccine include a 0.5 mL liquid injection, containing HPV16 and HPV18 proteins, with a minimum shelf life of 24 months [2] Group 2: Health Context - Cervical cancer is the fourth most common malignancy among women globally, with rising incidence and mortality rates in China, particularly among younger populations [2] - Evidence supports that HPV vaccination effectively prevents cervical cancer, with the best outcomes seen in younger age groups [2] - As of the end of 2024, 143 out of 194 WHO member countries (74%) have included the HPV vaccine in their national immunization programs [2] Group 3: Market Dynamics - Several regions in China have already initiated free HPV vaccination programs for eligible girls [3] - The timing for including the HPV vaccine in the national immunization program is deemed mature due to sufficient supply, accumulated efficacy data, and declining prices [3] - The procurement stipulates that only two manufacturers will be involved, which implies that one of the existing bivalent HPV vaccines will not be eligible for the bid [3]